New York, USA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- STAT Inhibitors Clinical Trial Analysis: DelveInsight Evaluates a Robust Pipeline as 22+ Influential Pharma Players to Set Foot in the Domain
The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Cancer and the growing research and development activities to develop STAT Inhibitor therapies in treating various Cancers drives the market. The companies developing the potential therapies in the last stage of development include Sumitomo Pharma America, Inc., Jiangsu Hengrui Medicine Co.,NeuroBo Pharmaceuticals, and several others.
DelveInsight’s 'STAT Inhibitors Pipeline Insight 2023' report provides comprehensive global coverage of pipeline STAT inhibitors in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the STAT inhibitors pipeline domain.
Key Takeaways from the STAT Inhibitors Pipeline Report
- DelveInsight’s STAT inhibitors pipeline report depicts a robust space with 22+ active players working to develop 25+ pipeline STAT inhibitors.
- Key STAT inhibitors companies such as Singh Biotechnology, AndroScience Corporation, Jiangsu Hengrui Medicine, Otsuka Pharmaceutica, Daewoong Pharmaceutical, Dexa Medica, Tvardi Therapeutic, Recludix Pharma, Sumitomo Pharma, Purple Biotech, Hyundai Bioscience, NeuroBo Pharmaceuticals Inc., Accendatech USA Inc., Moleculin Biotech, Inc., and others are evaluating new STAT inhibitors drugs to improve the treatment landscape.
- Promising pipeline STAT inhibitors such as SBT 101, SHR0302, OPB-111077, Niclosamide intramuscular depot, DLBS1033, TTI-101, TTI-102, TTI-109, Research programme: STAT3 transcription factor inhibitors, Research programme: STAT6 transcription factor inhibitor, Napabucasin, NT-219, CP-COV03, ANA001, ACT001, WP1066, REX 7117, and others are under different phases of STAT inhibitors clinical trials.
- In October 2023, Recludix Pharma presented preclinical data of Recludix’s STAT3 inhibitor REX-7117, which potently and selectively targets the STAT3 Src Homology 2 (SH2) domain. REX-7117 is a highly potent and selective STAT3 inhibitor. It provides durable STAT3 inhibition and maintains in vivo selectivity against other STAT proteins, even after the administration of multi-day oral dosing in a preclinical model.
- In July 2023, Recludix Pharma announced that the company has entered into a strategic collaboration with Sanofi to develop and commercialize first-in-class oral small molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory (I&I) diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases.
- In May 2022, the Food and Drug Administration (FDA) granted Orphan Drug designation to TT-101 for the treatment of idiopathic pulmonary fibrosis (IPF). TTI-101 is an orally-delivered, small molecule, STAT3 (signal transducer and activator of transcription 3) inhibitor.
Request a sample and discover the recent advances in STAT inhibitors drugs @ STAT Inhibitors Pipeline Report
The STAT inhibitors pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage STAT inhibitors drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the STAT inhibitors clinical trial landscape.
STAT Inhibitors Overview
STAT inhibitors are a class of pharmaceutical compounds designed to target and modulate the activity of Signal Transducer and Activator of Transcription (STAT) proteins. These proteins are critical components of cell signaling pathways that play a central role in mediating the effects of various cytokines, growth factors, and other extracellular signaling molecules. The STAT family comprises seven members: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6.
STAT proteins are involved in regulating a wide range of cellular processes, including cell growth, differentiation, apoptosis, immune responses, and inflammation. Dysregulation of STAT signaling has been implicated in various diseases, including cancer, autoimmune disorders, and inflammatory conditions. As a result, researchers have focused on developing STAT inhibitors as potential therapeutic agents to intervene in these pathological processes.
Research into STAT inhibitors has predominantly focused on cancer therapy, given the central role of STAT proteins in promoting cancer cell survival, proliferation, and resistance to apoptosis. Inhibiting aberrant STAT signaling can potentially hinder tumor growth and enhance the effectiveness of other anticancer treatments. However, the development of STAT inhibitors is a complex challenge due to the need for specificity, safety, and effectiveness.
Find out more about STAT inhibitors drugs @ STAT Inhibitors Analysis
A snapshot of the Pipeline STAT Inhibitors Drugs mentioned in the report:
| Drugs | Company | Phase | Indication | RoA |
| SHR0302 | Jiangsu Hengrui Medicine | Phase III | Rheumatoid arthritis | Oral |
| BBI608 | Sumitomo Pharma America, Inc. | Phase III | Gastric Cancer | Oral |
| ANA001 | NeuroBo Pharmaceuticals | Phase II/III | COVID-19 infections | Oral |
| WP1066 | Moleculin Biotech, Inc. | Phase II | Newly Diagnosed Glioblastoma | Oral |
| CP-COV03 | Hyundai Bioscience | Phase II | COVID-19 infections | NA |
| NT219 | Purple Biotech Ltd. | Phase I/II | Advanced Solid Tumors and Head and Neck Cancer | NA |
| OPB-111077 | Otsuka Pharmaceutical | Phase I | Solid tumors | Oral |
Learn more about the emerging STAT inhibitors @ STAT Inhibitors Clinical Trials
STAT Inhibitors Therapeutics Assessment
The STAT inhibitors pipeline report proffers an integral view of the emerging STAT inhibitors segmented by stage, product type, molecule type, and route of administration.
Scope of the STAT Inhibitors Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Infusion, Intradermal, Intramuscular, Intranasal, Oral, Parenteral, Subcutaneous, Topical
- Therapeutics Assessment By Molecule Type: Gene therapies, Small molecule, Vaccines, Polymers, Peptides, Monoclonal antibodies
- Key STAT Inhibitors Companies: Singh Biotechnology, AndroScience Corporation, Jiangsu Hengrui Medicine, Otsuka Pharmaceutica, Daewoong Pharmaceutical, Dexa Medica, Tvardi Therapeutic, Recludix Pharma, Sumitomo Pharma, Purple Biotech, Hyundai Bioscience, NeuroBo Pharmaceuticals Inc., Accendatech USA Inc., Moleculin Biotech, Inc. and others
- Key STAT Inhibitors Pipeline Therapies: SBT 101, SHR0302, OPB-111077, Niclosamide intramuscular depot, DLBS1033, TTI-102, TTI-109, Research programme: STAT3 transcription factor inhibitors, Research programme: STAT6 transcription factor inhibitor, Napabucasin, NT-219, CP-COV03, ANA001, ACT001, WP1066, REX 7117 and others
Dive deep into rich insights for new STAT inhibitors, visit @ STAT Inhibitors Drugs
Table of Contents
| 1. | STAT Inhibitors Pipeline Report Introduction |
| 2. | STAT Inhibitors Pipeline Report Executive Summary |
| 3. | STAT Inhibitors Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | STAT Inhibitors Clinical Trial Therapeutics |
| 6. | STAT Inhibitors Pipeline: Late-Stage Products (Pre-registration) |
| 7. | STAT Inhibitors Pipeline: Late-Stage Products (Phase III) |
| 8. | STAT Inhibitors Pipeline: Mid-Stage Products (Phase II) |
| 9. | STAT Inhibitors Pipeline: Early-Stage Products (Phase I) |
| 10. | STAT Inhibitors Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the STAT Inhibitors Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the STAT Inhibitors Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the STAT inhibitors pipeline therapeutics, reach out @ STAT Inhibitors Therapeutics
Related Reports
Immune Checkpoint Inhibitors Competitive Landscape
Immune Checkpoint Inhibitors Competitive Landscape and Market Forecast – 2032 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key immune checkpoint inhibitors companies, including Regeneron Pharmaceuticals, GlaxoSmithKline, Roche, Boehringer Ingelheim, Xencor, Inc., Taiga Biotechnologies, Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Dr. Reddys Laboratories, SA, NATCO Pharma Ltd., AstraZeneca, EMD Serono Research & Development Institute, Inc., Bristol-Myers Squibb, ImmuneSensor Therapeutics Inc., ImmunityBio, Inc., SQZ Biotechnologies, Teon Therapeutics, Inc., ALX Oncology, Astellas Pharma Inc, Seagen Inc., Hoffmann-La Roche, NextCure, Inc., MiNK Therapeutics, Genmab, BioNTech SE, STORM Therapeutics LTD, Suzhou Kintor Pharmaceutical Inc, Sanofi, Coordination Pharmaceuticals, Inc., among others.
Checkpoint Inhibitors Competitive Landscape
Checkpoint Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key checkpoint inhibitors companies, including BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, PharmaEngine, Vernalis, Array BioPharma, Genentech, Boehringer Ingelheim, Sentinel Oncology, Sierra Oncology, IMPACT Therapeutics, among others.
PD-1 Inhibitor Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 inhibitor companies, including Genmab, RemeGen, Alphamab, OxSonics therapeutics, Light Chain Bioscience, ImmuneOnco Biopharma, Alpine Immune Sciences, Shanghai Henlius Biotech, Inc., Ocean Biomedical, Akeso Biopharma, Lyvgen Biopharma, Prestige Biopharma, ONO PHARMACEUTICAL CO., LTD., among others.
PD-1 and PD-L1 Inhibitors Competitive Landscape
PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma, among others.
JAK Inhibitors Competitive Landscape
JAK Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, among others.
TIGIT Inhibitors Competitive Landscape
TIGIT Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TIGIT inhibitors companies, including Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
